Menu
Search
|

Menu

Close
X

Novan Inc NOVN.OQ (NASDAQ Stock Exchange Global Market)

2.68 USD
-0.17 (-5.96%)
As of 4:00 PM EDT
Previous Close 2.85
Open 2.75
Volume 18,285
3m Avg Volume 28,075
Today’s High 2.89
Today’s Low 2.66
52 Week High 3.23
52 Week Low 0.65
Shares Outstanding (mil) 26.07
Market Capitalization (mil) 65.70
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY19
1
FY18
6
FY17
3
FY16
0
EPS (USD)
FY19
-0.270
FY18
-0.495
FY17
-2.299
FY16
-3.448
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.85
Price to Sales (TTM)
vs sector
10.21
7.90
Price to Book (MRQ)
vs sector
--
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
--
17.64
LT Debt to Equity (MRQ)
vs sector
--
12.61
Return on Investment (TTM)
vs sector
-57.91
12.69
Return on Equity (TTM)
vs sector
-321.23
17.13

EXECUTIVE LEADERSHIP

Robert Ingram
Independent Chairman of the Board, Since 2011
Salary: --
Bonus: --
Paula Stafford
President, Chief Operating Officer, Since 2019
Salary: --
Bonus: --
G Kelly Martin
Interim Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
John Gay
Principal Financial Officer, Secretary, Since 2019
Salary: --
Bonus: --
Carri Geer
Senior Vice President and Chief Technology Officer, Since 2019
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

4105 Hopson Rd
MORRISVILLE   NC   27560-9018

Phone: +1919.4858080

Novan, Inc. is a clinical development-stage biotechnology company. The Company is focused on leveraging nitric oxide’s naturally occurring anti-microbial and immunomodulatory mechanisms of action to treat a range of diseases. The Company has created a Nitricil technology platform enabling the development of new chemical entities (NCEs) with delivery of nitric oxide. The Company’s two key components of its nitric oxide platform are its Nitricil technology, which drives the creation of NCEs, and its formulation science, both of which it uses to tune its product candidates for specific indications. Novan’s Nitricil technology enables it to store large amounts of nitric oxide gas in a stable, solid form by chemically loading it on a macromolecule, or polymer. The nitric oxide platform has produced a portfolio that includes the various clinical stage dermatology product candidates: SB204, SB206, SB208 and SB414.

SPONSORED STORIES